Uniseed
Uniseed is a venture capital firm founded in 2000 and based in Saint Lucia, Australia. Established as a joint initiative between the University of Melbourne and the University of Queensland, Uniseed focuses on investing in technology start-ups, particularly those emerging from its partner research organizations. The firm operates through multiple funds, with its latest, launched in 2015, involving the University of Sydney and CSIRO alongside its founding partners. Uniseed's investment strategy emphasizes long-term partnerships with academic institutions, providing tailored commercialization services that enhance their capabilities. The firm has made over 20 investments, typically ranging from $250,000 to $2.5 million, and has a track record of successful exits. Uniseed's commitment to supporting research commercialization is underscored by its significant contributions to the research ecosystem, which includes nearly $4 billion in research spending and numerous invention disclosures. The firm prioritizes a balanced approach to measuring success, focusing on financial returns, the establishment of viable start-ups, and the enhancement of commercialization processes for its partners.
73 past transactions
Celosia Therapeutics
Series A in 2024
Celosia Therapeutics is a gene therapy company focused on developing treatments for a variety of neurodegenerative diseases, including motor neuron disease, epilepsy, and Alzheimer's disease. By leveraging advancements in gene therapies and a deeper understanding of the molecular pathways involved in these conditions, Celosia aims to provide innovative therapeutic options where few exist. The company is dedicated to modifying the neuronal microenvironment to enhance patient outcomes and combat the challenges posed by these debilitating diseases.
Kinoxis Therapeutics
Series B in 2024
Kinoxis Therapeutics is an early-stage biotechnology company based in Australia focused on developing novel therapeutic compounds for substance use disorders and other central nervous system conditions. The company has licensed its lead candidate, which has shown significant anti-addictive and prosocial effects in various animal models, from the University of Sydney. As it advances through pre-clinical testing, Kinoxis aims to address the growing need for effective treatments for opioid withdrawal and other substance-related issues. Their comprehensive medicinal chemistry and screening programs are designed to support the treatment of methamphetamine use disorder and nicotine withdrawal, ultimately contributing to improved outcomes in neurological and psychiatric care.
Diraq
Series A in 2024
Diraq aims to redefine scalable quantum computing and bring practical commercial applications to the world via billions of qubits on a single chip, compared to the hundreds of qubits that exist today. The company will be an end-to-end quantum computing provider, offering quantum hardware and software as a full stack, cloud accessible service.
Aravax
Series B in 2024
Aravax is an early-stage biotechnology company based in Melbourne, Australia, dedicated to developing a safe and effective treatment for peanut allergies. Founded in May 2015 through the acquisition of intellectual property from Alfred Health and Monash University, Aravax employs proprietary technology aimed at resetting the immune system to tolerate peanuts without triggering allergic reactions. The company's innovative approach seeks to eliminate the risk of life-threatening responses to peanuts, allowing patients to undergo treatment and potentially overcome mild symptoms such as itchiness, rash, and gastrointestinal upset.
BioScout
Seed Round in 2023
BioScout develops an integrated hardware and software platform focused on the detection and prevention of airborne diseases in agricultural settings. The company employs advanced air sampling, mapping, and data analytics, utilizing strategically placed sensors in farm fields to monitor disease spread. This patented platform provides farmers with crucial data through a disease dashboard and sends text message alerts for high threat levels. By enabling proactive disease management, BioScout helps farmers maximize yield and quality while improving spray efficiency and tracking disease outbreaks more effectively.
ResusRight
Seed Round in 2023
ResusRight is a company that specializes in the design and manufacture of monitoring devices tailored for infants. Its primary focus is on developing medical technology that offers quantitative feedback to healthcare professionals regarding their resuscitation techniques. By providing this critical support during the resuscitation of newborns at birth, ResusRight aims to reduce the risk of death and disability in infants who require immediate medical intervention. The company's innovative solutions are intended to enhance the effectiveness of clinical practices, ultimately improving outcomes for vulnerable newborns.
Ferronova
Series B in 2023
Ferronova Pty Ltd, established in 2016 and based in Salisbury South, Australia, specializes in manufacturing innovative medical devices for cancer diagnosis. The company produces surgical oncology tracer devices, utilizing magnetic nanoparticles visible on MRI, enabling non-invasive detection and surgical staging of complex cancers, such as head, neck, and colorectal, at earlier stages.
Morse Micro
Series B in 2022
Morse Micro is a wireless integrated circuit solutions company focused on reinventing Wi-Fi for the Internet of Things (IoT). Founded by industry experts including Wi-Fi pioneers, the company is headquartered in Australia with additional offices in China and the United States. Morse Micro specializes in low-power wireless chips that enhance Wi-Fi connectivity across a wide range of IoT applications, such as surveillance systems, access control, industrial automation, and mobile devices. Their innovative technology allows for smaller and more cost-effective chips, facilitating a robust IoT ecosystem that supports connected devices operating over greater distances. The company's diverse team and strong portfolio of intellectual property position it as a key player in the evolving IoT market.
Tiny Bright Things
Seed Round in 2022
Tiny Bright Things is a Melbourne-based company founded in 2020 by Ray Dagastine and Chris Bolton, specializing in innovative microscopy technology known as Halo microscopy. This technology significantly enhances the imaging and measurement of small or transparent objects, catering to the needs of industrial manufacturers and researchers across various fields. In particular, it serves sectors such as agrichemicals and pharmaceuticals, where the size and shape of powders are crucial. Additionally, the technology is instrumental in nanotechnology and life sciences, enabling accurate analysis of samples that are often tiny or transparent. By allowing imaging and measurement down to the scale of viruses, drug particles, and nanotubes without altering the samples, Tiny Bright Things supports effective research and development at various stages of discovery.
Analog Quantum Circuits
Seed Round in 2022
Analog Quantum Circuits specializes in the manufacture of analog components for solid-state quantum computers. The company develops core microwave technologies and advanced superconducting devices tailored for superconducting quantum computing applications. By focusing on the creation and fabrication of these essential elements, Analog Quantum Circuits aims to support scientific advancements and address the increasing demands of the burgeoning quantum computing sector.
OccuRx
Series B in 2022
OccuRx is a Melbourne-based biopharmaceutical company founded in 2014, focusing on the development of innovative therapeutic strategies for ophthalmic disorders linked to retinal fibrosis. The company aims to address the unmet clinical need for targeted ocular therapies through its proprietary small-molecule drugs, which are designed to enhance visual acuity and prevent vision loss in inflammatory and degenerative eye diseases. OccuRx's strategies enable healthcare professionals to prevent the growth of new and abnormal blood vessels and reduce inflammation in the retina, thereby improving patient outcomes in the treatment of these conditions.
Morse Micro
Series B in 2022
Morse Micro is a wireless integrated circuit solutions company focused on reinventing Wi-Fi for the Internet of Things (IoT). Founded by industry experts including Wi-Fi pioneers, the company is headquartered in Australia with additional offices in China and the United States. Morse Micro specializes in low-power wireless chips that enhance Wi-Fi connectivity across a wide range of IoT applications, such as surveillance systems, access control, industrial automation, and mobile devices. Their innovative technology allows for smaller and more cost-effective chips, facilitating a robust IoT ecosystem that supports connected devices operating over greater distances. The company's diverse team and strong portfolio of intellectual property position it as a key player in the evolving IoT market.
BioScout
Seed Round in 2022
BioScout develops an integrated hardware and software platform focused on the detection and prevention of airborne diseases in agricultural settings. The company employs advanced air sampling, mapping, and data analytics, utilizing strategically placed sensors in farm fields to monitor disease spread. This patented platform provides farmers with crucial data through a disease dashboard and sends text message alerts for high threat levels. By enabling proactive disease management, BioScout helps farmers maximize yield and quality while improving spray efficiency and tracking disease outbreaks more effectively.
Forcite Helmet Systems
Series A in 2022
Forcite Helmet Systems Pty Ltd, founded in 2013 and based in Haymarket, Australia, specializes in manufacturing smart helmets designed to enhance motorcycle safety. These helmets feature an integrated camera system, navigation, intercom, and active noise-cancelling technology, aiming to address the safety gaps commonly associated with motorcycling. By leveraging advanced sensor technology and the Forcite Command software platform, the company seeks to make motorcycling significantly safer compared to traditional helmets. The lightweight carbon fiber construction of the helmets further contributes to their innovative design. Forcite is committed to improving the riding experience through its cutting-edge helmet solutions.
Currus Biologics
Series A in 2021
Currus Biologics is a biotechnology company focused on developing CAR-T cell therapies aimed at treating solid tumors. The company specializes in creating bispecific antigen-presenting and T-cell engagers to target various cancers, including breast, colon, pancreatic, and prostate cancers. By innovating chimeric antigen receptors, Currus Biologics seeks to enhance the efficacy of cancer treatments, enabling patients with solid tumor indications to receive more effective therapies.
Ena Respiratory
Venture Round in 2021
Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, established in 2020. The company focuses on developing synthetic innate immunomodulators aimed at transforming the treatment and prevention of respiratory infections. Ena Respiratory's novel synthetic Toll-like receptor 2 (TLR2) receptor agonists are designed to activate the innate immune system specifically in the respiratory tract. This innovative approach enables targeted delivery to the airways, helping to prevent the dissemination of viral and bacterial infections to the lungs. By enhancing the immune response, Ena Respiratory aims to protect patients with pre-existing lung conditions from severe complications associated with respiratory infections.
Ena Respiratory
Venture Round in 2021
Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, established in 2020. The company focuses on developing synthetic innate immunomodulators aimed at transforming the treatment and prevention of respiratory infections. Ena Respiratory's novel synthetic Toll-like receptor 2 (TLR2) receptor agonists are designed to activate the innate immune system specifically in the respiratory tract. This innovative approach enables targeted delivery to the airways, helping to prevent the dissemination of viral and bacterial infections to the lungs. By enhancing the immune response, Ena Respiratory aims to protect patients with pre-existing lung conditions from severe complications associated with respiratory infections.
Kinoxis Therapeutics
Series A in 2020
Kinoxis Therapeutics is an early-stage biotechnology company based in Australia focused on developing novel therapeutic compounds for substance use disorders and other central nervous system conditions. The company has licensed its lead candidate, which has shown significant anti-addictive and prosocial effects in various animal models, from the University of Sydney. As it advances through pre-clinical testing, Kinoxis aims to address the growing need for effective treatments for opioid withdrawal and other substance-related issues. Their comprehensive medicinal chemistry and screening programs are designed to support the treatment of methamphetamine use disorder and nicotine withdrawal, ultimately contributing to improved outcomes in neurological and psychiatric care.
Ena Respiratory
Series A in 2020
Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, established in 2020. The company focuses on developing synthetic innate immunomodulators aimed at transforming the treatment and prevention of respiratory infections. Ena Respiratory's novel synthetic Toll-like receptor 2 (TLR2) receptor agonists are designed to activate the innate immune system specifically in the respiratory tract. This innovative approach enables targeted delivery to the airways, helping to prevent the dissemination of viral and bacterial infections to the lungs. By enhancing the immune response, Ena Respiratory aims to protect patients with pre-existing lung conditions from severe complications associated with respiratory infections.
Ferronova
Series A in 2020
Ferronova Pty Ltd, established in 2016 and based in Salisbury South, Australia, specializes in manufacturing innovative medical devices for cancer diagnosis. The company produces surgical oncology tracer devices, utilizing magnetic nanoparticles visible on MRI, enabling non-invasive detection and surgical staging of complex cancers, such as head, neck, and colorectal, at earlier stages.
Wildlife Drones
Venture Round in 2019
Wildlife Drones Pty. Ltd., founded in 2016 and headquartered in Macquarie, Australia, specializes in the design and development of innovative animal radio-tracking systems using drone technology. With over 25 years of experience in ecological and scientific research, the company addresses the challenges associated with tracking highly mobile animals. Traditional ground-based radio-tracking methods often require significant effort to achieve clear signals, which can be costly and labor-intensive. By utilizing drones, Wildlife Drones enhances the altitude from which data is collected, significantly improving the quality and quantity of radio-tracking information. This technology enables wildlife researchers, conservationists, and environmental consultants to effectively monitor endangered species, track invasive species, and locate livestock on remote properties, ultimately aiding in the prevention and mitigation of environmental damage.
Aurtra
Seed Round in 2019
Aurtra Pty Ltd, established in 2016 and headquartered in Corinda, Australia, specializes in cloud-based asset management solutions for power distribution networks. The company offers a dashboard that provides real-time, fleet-wide analysis of transformers, enabling asset managers and engineers to extend transformer life, reduce capital costs, and make informed decisions regarding maintenance, replacement, and load management. Aurtra's technology, built upon world-class research from the University of Queensland, helps mitigate catastrophic failures and improves risk management through online condition monitoring and advanced analysis.
OccuRx
Series A in 2019
OccuRx is a Melbourne-based biopharmaceutical company founded in 2014, focusing on the development of innovative therapeutic strategies for ophthalmic disorders linked to retinal fibrosis. The company aims to address the unmet clinical need for targeted ocular therapies through its proprietary small-molecule drugs, which are designed to enhance visual acuity and prevent vision loss in inflammatory and degenerative eye diseases. OccuRx's strategies enable healthcare professionals to prevent the growth of new and abnormal blood vessels and reduce inflammation in the retina, thereby improving patient outcomes in the treatment of these conditions.
Morse Micro
Series A in 2019
Morse Micro is a wireless integrated circuit solutions company focused on reinventing Wi-Fi for the Internet of Things (IoT). Founded by industry experts including Wi-Fi pioneers, the company is headquartered in Australia with additional offices in China and the United States. Morse Micro specializes in low-power wireless chips that enhance Wi-Fi connectivity across a wide range of IoT applications, such as surveillance systems, access control, industrial automation, and mobile devices. Their innovative technology allows for smaller and more cost-effective chips, facilitating a robust IoT ecosystem that supports connected devices operating over greater distances. The company's diverse team and strong portfolio of intellectual property position it as a key player in the evolving IoT market.
Agerris
Seed Round in 2019
Agerris Pty Ltd, established in 2005 and based in Chippendale, Australia, specializes in designing and manufacturing modular robotics for the agricultural industry. The company's flagship product, Swagbot, is a modular robot that autonomously monitors and addresses weed issues, detects food, herds livestock, and assesses crops using computer vision. Additionally, Agerris develops an AI-based platform, Digital Farmhand, which enables farm machinery to detect and assess weeds, count individual fruit, nuts, crops, and animals. The company's products cater to various applications, including tree crop and row crop automation, intelligent spraying, livestock monitoring, and fruit and crop detection.
Forcite Helmet Systems
Seed Round in 2019
Forcite Helmet Systems Pty Ltd, founded in 2013 and based in Haymarket, Australia, specializes in manufacturing smart helmets designed to enhance motorcycle safety. These helmets feature an integrated camera system, navigation, intercom, and active noise-cancelling technology, aiming to address the safety gaps commonly associated with motorcycling. By leveraging advanced sensor technology and the Forcite Command software platform, the company seeks to make motorcycling significantly safer compared to traditional helmets. The lightweight carbon fiber construction of the helmets further contributes to their innovative design. Forcite is committed to improving the riding experience through its cutting-edge helmet solutions.
Wildlife Drones
Seed Round in 2019
Wildlife Drones Pty. Ltd., founded in 2016 and headquartered in Macquarie, Australia, specializes in the design and development of innovative animal radio-tracking systems using drone technology. With over 25 years of experience in ecological and scientific research, the company addresses the challenges associated with tracking highly mobile animals. Traditional ground-based radio-tracking methods often require significant effort to achieve clear signals, which can be costly and labor-intensive. By utilizing drones, Wildlife Drones enhances the altitude from which data is collected, significantly improving the quality and quantity of radio-tracking information. This technology enables wildlife researchers, conservationists, and environmental consultants to effectively monitor endangered species, track invasive species, and locate livestock on remote properties, ultimately aiding in the prevention and mitigation of environmental damage.
PERKii
Venture Round in 2018
PERKii specializes in producing probiotic beverages designed to deliver live and protected probiotics effectively. Utilizing a unique Progel™ technology, developed by scientists at The University of Queensland, PERKii's drinks encapsulate probiotics in microgels that withstand stomach acid, ensuring their survival and efficacy in the digestive system. Each refreshing water-based drink contains only 26 calories and a modest amount of sugar derived from apples, making it a healthier alternative in the beverage market. By combining natural flavors with advanced probiotic delivery, PERKii aims to enhance gut health, support immunity, and provide a satisfying taste experience for consumers.
Exonate
Seed Round in 2018
Exonate Limited is a private biotech company based in Duxford, United Kingdom, specializing in the discovery and development of small molecule drugs aimed at modulating alternative messenger RNA splicing for ophthalmological applications. Founded in 2013, the company emerged from the University of Nottingham and is focused on addressing retinal vascular diseases, particularly diabetic macular oedema (DMO) and wet age-related macular degeneration (wAMD). Exonate's lead program utilizes small molecule inhibitors that selectively target serine/threonine-protein kinase 1 to inhibit the production of pro-angiogenic vascular endothelial growth factor (VEGF) splice variants. This innovative approach aims to improve therapeutic outcomes and offers a potential alternative to current treatment methods, such as anti-VEGF injections and laser surgery. With a preclinical candidate drug already nominated, Exonate is advancing its research through regulatory toxicology and safety pharmacology studies to facilitate clinical evaluation. The company is backed by an experienced management team with expertise in medicine and drug development.
Q-Sera
Venture Round in 2018
Q-Sera Pty Ltd specializes in developing innovative blood collection tubes that enhance the efficiency of blood clotting, utilizing snake venom-derived proteins. This technology accelerates the clotting process, allowing for the rapid production of high-quality serum essential for biochemical analysis and clinical diagnostics. The company's approach leverages potent prothrombin activators isolated from the venom of certain snakes, including the Australian Taipan. These proteins are manufactured through modified cell lines using standard pharmaceutical processes, ensuring reliability and effectiveness. By improving the speed and quality of serum production, Q-Sera's technology aims to optimize laboratory efficiency and enhance patient care.
Kinoxis Therapeutics
Seed Round in 2018
Kinoxis Therapeutics is an early-stage biotechnology company based in Australia focused on developing novel therapeutic compounds for substance use disorders and other central nervous system conditions. The company has licensed its lead candidate, which has shown significant anti-addictive and prosocial effects in various animal models, from the University of Sydney. As it advances through pre-clinical testing, Kinoxis aims to address the growing need for effective treatments for opioid withdrawal and other substance-related issues. Their comprehensive medicinal chemistry and screening programs are designed to support the treatment of methamphetamine use disorder and nicotine withdrawal, ultimately contributing to improved outcomes in neurological and psychiatric care.
Nexgen Plants
Venture Round in 2018
Nexgen Plants is an emerging company focused on developing innovative plant traits that provide non-genetically modified solutions for various agricultural challenges. By utilizing a proprietary transformation technique, Nexgen aims to create crops that are resistant to viruses and fungi, as well as those that are salt-tolerant and enhanced in anthocyanin content. Their work addresses the needs of agriculture-dependent communities globally, helping them improve yields and adapt to new market opportunities. The company is dedicated to fostering the next generation of valuable crops for diverse applications, including food, fiber, energy, and ornamental purposes.
Certa
Seed Round in 2018
Certa is an operational management platform that specializes in third-party lifecycle management. The company offers a fully integrated suite of products designed to optimize workflows related to third-party interactions. Its automated software-as-a-service (SaaS) platform facilitates various business-to-business processes, including onboarding, due diligence, risk mitigation, and ongoing monitoring of third-party relationships. By providing tools for supplier lifecycle management, Certa enables businesses to effectively manage risks, ensure compliance, and streamline operations with their external partners on a global scale.
Certa Therapeutics
Grant in 2018
Certa Therapeutics, established in 2017 and headquartered in Melbourne, Australia, is a biotechnology company specializing in the development of precision medicines for fibrotic diseases, with a primary focus on kidney disorders. The company employs genetic analysis to identify patients at risk of developing kidney fibrosis, a precursor to end-stage kidney failure. Certa's drug pipeline targets a key receptor driving kidney fibrosis, aiming to halt or reverse the scarring process and prevent the need for dialysis or transplantation. Currently in the clinical stage, the company's mission is to transform the treatment landscape for fibrotic diseases by enabling early intervention and improving patient outcomes.
Kinoxis Therapeutics
Venture Round in 2018
Kinoxis Therapeutics is an early-stage biotechnology company based in Australia focused on developing novel therapeutic compounds for substance use disorders and other central nervous system conditions. The company has licensed its lead candidate, which has shown significant anti-addictive and prosocial effects in various animal models, from the University of Sydney. As it advances through pre-clinical testing, Kinoxis aims to address the growing need for effective treatments for opioid withdrawal and other substance-related issues. Their comprehensive medicinal chemistry and screening programs are designed to support the treatment of methamphetamine use disorder and nicotine withdrawal, ultimately contributing to improved outcomes in neurological and psychiatric care.
Cardihab
Seed Round in 2017
Cardihab, established in 2016 and based in Fortitude Valley, Australia, specializes in digital cardiac rehabilitation solutions. It offers a cloud-based portal and smartphone app, enabling clinicians to manage patient data, track goals, and connect to sensors. This allows for remote cardiac rehabilitation, reducing clinic visits to just the initial and final assessments, and making the process more convenient and flexible for patients.
Brisbane Materials
Series B in 2017
Brisbane Materials Technology Pty Ltd., founded in 2005 and based in St Lucia, Australia, specializes in the manufacturing of anti-reflective coatings for various applications, notably in lighting and solar power. The company emerged from the University of Queensland and has benefited from significant investment in technology and application expertise over the years. Brisbane Materials focuses on producing innovative, low-cost optical coatings, such as porous silica-based anti-reflective coatings, using a patented synthesis process that operates at room temperature and atmospheric pressure. This technology not only enhances the efficiency of solar panel covers, both photovoltaic and solar thermal, but also provides cost-effective solutions for lighting applications. As a subsidiary of XeroCoat, Inc., Brisbane Materials aims to expand its offerings by applying its unique coatings across a broader range of materials and applications.
QUE Oncology
Series A in 2017
QUE Oncology, Inc. is a biotechnology company based in Atlanta, Georgia, founded in 2013 through a collaboration between Emory University and The University of Queensland's research commercialization company, UniQuest. The company focuses on developing innovative drug therapies for cancer, particularly breast and prostate cancer, by licensing intellectual property from both institutions. QUE's leading drug candidate, Q-122, is currently in Phase 1b clinical development and targets hot flashes in women undergoing anti-estrogen therapy for breast cancer. This compound is a non-hormonal, orally bioavailable small molecule designed to alleviate moderate to severe vasomotor symptoms, including night sweats. QUE Oncology's research pipeline also encompasses projects related to prostate cancer, melanoma, and cancer pain, aiming to meet significant unmet medical needs in oncology.
Ena Respiratory
Venture Round in 2017
Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, established in 2020. The company focuses on developing synthetic innate immunomodulators aimed at transforming the treatment and prevention of respiratory infections. Ena Respiratory's novel synthetic Toll-like receptor 2 (TLR2) receptor agonists are designed to activate the innate immune system specifically in the respiratory tract. This innovative approach enables targeted delivery to the airways, helping to prevent the dissemination of viral and bacterial infections to the lungs. By enhancing the immune response, Ena Respiratory aims to protect patients with pre-existing lung conditions from severe complications associated with respiratory infections.
Smart Sparrow
Series C in 2017
Smart Sparrow operates an innovative e-learning platform that allows educators and organizations to create interactive and adaptive courseware across various subjects, such as digital literacy, computer science, engineering, finance, and soft skills. Founded in December 2010 by Ariel Shoham, Dror Ben-Haim, Shaowei Ho, and Zack Belinson, the company is headquartered in Surry Hills, Australia, with an additional office in San Francisco, California. The platform features a user-friendly, drag-and-drop authoring tool accessible through any web browser, enabling educators to build customized courses, define personalized learning paths for students, and collaborate in real-time. Additionally, Smart Sparrow provides pre-made templates to streamline the course creation process, serving a diverse range of institutions both locally and internationally.
Exonate
Angel Round in 2016
Exonate Limited is a private biotech company based in Duxford, United Kingdom, specializing in the discovery and development of small molecule drugs aimed at modulating alternative messenger RNA splicing for ophthalmological applications. Founded in 2013, the company emerged from the University of Nottingham and is focused on addressing retinal vascular diseases, particularly diabetic macular oedema (DMO) and wet age-related macular degeneration (wAMD). Exonate's lead program utilizes small molecule inhibitors that selectively target serine/threonine-protein kinase 1 to inhibit the production of pro-angiogenic vascular endothelial growth factor (VEGF) splice variants. This innovative approach aims to improve therapeutic outcomes and offers a potential alternative to current treatment methods, such as anti-VEGF injections and laser surgery. With a preclinical candidate drug already nominated, Exonate is advancing its research through regulatory toxicology and safety pharmacology studies to facilitate clinical evaluation. The company is backed by an experienced management team with expertise in medicine and drug development.
PERKii
Venture Round in 2016
PERKii specializes in producing probiotic beverages designed to deliver live and protected probiotics effectively. Utilizing a unique Progel™ technology, developed by scientists at The University of Queensland, PERKii's drinks encapsulate probiotics in microgels that withstand stomach acid, ensuring their survival and efficacy in the digestive system. Each refreshing water-based drink contains only 26 calories and a modest amount of sugar derived from apples, making it a healthier alternative in the beverage market. By combining natural flavors with advanced probiotic delivery, PERKii aims to enhance gut health, support immunity, and provide a satisfying taste experience for consumers.
MetaBloQ
Seed Round in 2016
MetaBloQ is a biotechnology company dedicated to the development of innovative drugs aimed at treating various types of cancer, including triple-negative breast cancer, prostate cancer, and melanoma. The company's focus is on creating therapies that effectively block specific metabolic processes in cancer cells while minimizing toxicity to healthy, non-cancerous cells. This approach seeks to provide patients with safer and more tolerable treatment options, enhancing the overall efficacy of cancer care.
OccuRx
Venture Round in 2015
OccuRx is a Melbourne-based biopharmaceutical company founded in 2014, focusing on the development of innovative therapeutic strategies for ophthalmic disorders linked to retinal fibrosis. The company aims to address the unmet clinical need for targeted ocular therapies through its proprietary small-molecule drugs, which are designed to enhance visual acuity and prevent vision loss in inflammatory and degenerative eye diseases. OccuRx's strategies enable healthcare professionals to prevent the growth of new and abnormal blood vessels and reduce inflammation in the retina, thereby improving patient outcomes in the treatment of these conditions.
ProGel
Series B in 2014
ProGel Pty Ltd, founded in 2009 and based in Brisbane, Australia, specializes in the development and manufacture of innovative microencapsulation technology. The company emerged from research at the University of Queensland, focusing on a method that allows for the encapsulation of active ingredients for use in foods, cosmetics, and pharmaceuticals. ProGel's calcium alginate microgels are designed to withstand gastric conditions, enabling the effective delivery of high-value additives in functional foods like probiotic drinks and omega-3 enriched products. This technology not only ensures that the encapsulated ingredients remain undetectable to consumers but also provides a cost-effective solution for manufacturers. ProGel is positioned to tap into rapidly growing multi-billion dollar markets, with targeted sectors experiencing growth rates exceeding 10% annually.
TenasiTech
Angel Round in 2014
TenasiTech is a provider of composite polymers tailored for various industries, including engineering, sporting, automotive, and construction. The company specializes in developing polymer products that exhibit mechanical strength, creep resistance, compressive set chemical resistance, and thermo-stability. These properties enhance the durability of engineering thermoplastics, making them more resistant to surface damage and suitable for demanding applications across multiple sectors.
Spinifex Pharmaceuticals
Series C in 2014
Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.
Hatchtech
Venture Round in 2013
Hatchtech is an Australian company focused on developing innovative pest control solutions through its proprietary technology platform. The company's patented approach targets the egg hatch of pest species, effectively disrupting their lifecycle with a novel mode of action. Hatchtech's technology is designed to address various invertebrate pests, including ectoparasites such as head lice, as well as pests affecting animals, crops, and the built environment. Their flagship product offers a single-dose treatment that eliminates both head lice and their eggs in one application, providing an effective solution for infestations.
Nexgen Plants
Series A in 2013
Nexgen Plants is an emerging company focused on developing innovative plant traits that provide non-genetically modified solutions for various agricultural challenges. By utilizing a proprietary transformation technique, Nexgen aims to create crops that are resistant to viruses and fungi, as well as those that are salt-tolerant and enhanced in anthocyanin content. Their work addresses the needs of agriculture-dependent communities globally, helping them improve yields and adapt to new market opportunities. The company is dedicated to fostering the next generation of valuable crops for diverse applications, including food, fiber, energy, and ornamental purposes.
Hydrexia
Series B in 2013
Hydrexia is an Australian company that has successfully designed, built, and tested systems that stores hydrogen in solid form, based on a proprietary magnesium alloy.
TenasiTech
Grant in 2012
TenasiTech is a provider of composite polymers tailored for various industries, including engineering, sporting, automotive, and construction. The company specializes in developing polymer products that exhibit mechanical strength, creep resistance, compressive set chemical resistance, and thermo-stability. These properties enhance the durability of engineering thermoplastics, making them more resistant to surface damage and suitable for demanding applications across multiple sectors.
Q-Sera
Series A in 2012
Q-Sera is an anti-hair loss therapy platform.
Hatchtech
Venture Round in 2012
Hatchtech is an Australian company focused on developing innovative pest control solutions through its proprietary technology platform. The company's patented approach targets the egg hatch of pest species, effectively disrupting their lifecycle with a novel mode of action. Hatchtech's technology is designed to address various invertebrate pests, including ectoparasites such as head lice, as well as pests affecting animals, crops, and the built environment. Their flagship product offers a single-dose treatment that eliminates both head lice and their eggs in one application, providing an effective solution for infestations.
Spinifex Pharmaceuticals
Series B in 2011
Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.
Verva Pharmaceuticals
Venture Round in 2011
Verva Pharmaceuticals Ltd. (“Verva”) was formed in December, 2007 by consolidation of key diabetes assets, discovery technologies and targets resident in Autogen Research Ltd. (formerly the diabetes-focused subsidiary of ChemGenex Pharmaceuticals) with those of obesity drug development company Adipogen Pharmaceuticals Pty Ltd. The combined product portfolio, technologies and expertise provide a substantial opportunity for rapid clinical progress and growth in high-value markets with a significant unmet medical need. Verva operates in a completely virtual mode, managed by a CEO and Directors with extensive international product development and partnering experience. Verva’s founding research was undertaken at the Metabolic Research Unit of Deakin University in Geelong, Australia; a state-of-the-art facility providing access to key in vitro and in vivo models and capabilities. Verva has subsequently engaged expert scientists, clinicians, technical advisers and contract research organisations worldwide to implement the Company’s research and development strategy.
Smart Sparrow
Series A in 2011
Smart Sparrow operates an innovative e-learning platform that allows educators and organizations to create interactive and adaptive courseware across various subjects, such as digital literacy, computer science, engineering, finance, and soft skills. Founded in December 2010 by Ariel Shoham, Dror Ben-Haim, Shaowei Ho, and Zack Belinson, the company is headquartered in Surry Hills, Australia, with an additional office in San Francisco, California. The platform features a user-friendly, drag-and-drop authoring tool accessible through any web browser, enabling educators to build customized courses, define personalized learning paths for students, and collaborate in real-time. Additionally, Smart Sparrow provides pre-made templates to streamline the course creation process, serving a diverse range of institutions both locally and internationally.
Otifex
Series A in 2010
Otifex Therapeutics Pty Ltd is an Australian specialty pharmaceutical company focused on developing innovative treatments for Otitis Media with Effusion (OME), a common cause of acquired hearing loss in children. Currently, the standard treatment for OME often involves surgical insertion of grommets to regulate middle ear pressure, with no effective non-invasive alternatives available. Otifex is pioneering a novel nasal spray aimed at facilitating the natural equalization of middle ear pressure, potentially allowing OME to resolve without surgery. The company also produces nasal spray products and tablets based on betahistine, which is known for its use in treating Meniere's Disease and Vestibular Vertigo. These formulations are designed to aid in the clearance of fluid from the middle ear, offering a promising solution for children suffering from OME.
Hatchtech
Venture Round in 2010
Hatchtech is an Australian company focused on developing innovative pest control solutions through its proprietary technology platform. The company's patented approach targets the egg hatch of pest species, effectively disrupting their lifecycle with a novel mode of action. Hatchtech's technology is designed to address various invertebrate pests, including ectoparasites such as head lice, as well as pests affecting animals, crops, and the built environment. Their flagship product offers a single-dose treatment that eliminates both head lice and their eggs in one application, providing an effective solution for infestations.
BT Imaging
Series A in 2010
BT Imaging is a leading manufacturer of electrical-inspection equipment tailored for the photovoltaic manufacturing industry. The company specializes in luminescence-based inspection and quality control systems designed to enhance the production processes of silicon blocks, wafers, and solar cells. By providing advanced tools for research, product development, and manufacturing inspection, BT Imaging enables its clients to improve factory yield and increase the efficiency of solar cells. Their solutions support the overall design and production of solar modules, contributing to advancements in the solar energy sector.
ProGel
Series A in 2010
ProGel Pty Ltd, founded in 2009 and based in Brisbane, Australia, specializes in the development and manufacture of innovative microencapsulation technology. The company emerged from research at the University of Queensland, focusing on a method that allows for the encapsulation of active ingredients for use in foods, cosmetics, and pharmaceuticals. ProGel's calcium alginate microgels are designed to withstand gastric conditions, enabling the effective delivery of high-value additives in functional foods like probiotic drinks and omega-3 enriched products. This technology not only ensures that the encapsulated ingredients remain undetectable to consumers but also provides a cost-effective solution for manufacturers. ProGel is positioned to tap into rapidly growing multi-billion dollar markets, with targeted sectors experiencing growth rates exceeding 10% annually.
Manjrasoft
Venture Round in 2009
Manjrasoft Pty. Ltd. is a Melbourne-based company that specializes in commercializing grid and cloud computing software technologies developed by the Grid Computing and Distributed Systems Laboratory. Founded in 2008, the company provides Aneka, a platform designed for rapid application development and workload distribution, which enhances the performance of software applications requiring high computational power. Manjrasoft offers various solutions, including distributed 3D rendering using Autodesk Maya, educational and training tools, and cloud computing consultancy services. The company serves diverse sectors such as engineering, entertainment, gaming, life sciences, and finance, enabling organizations to efficiently build, accelerate, and manage their applications and cloud environments.
Verva Pharmaceuticals
Venture Round in 2009
Verva Pharmaceuticals Ltd. (“Verva”) was formed in December, 2007 by consolidation of key diabetes assets, discovery technologies and targets resident in Autogen Research Ltd. (formerly the diabetes-focused subsidiary of ChemGenex Pharmaceuticals) with those of obesity drug development company Adipogen Pharmaceuticals Pty Ltd. The combined product portfolio, technologies and expertise provide a substantial opportunity for rapid clinical progress and growth in high-value markets with a significant unmet medical need. Verva operates in a completely virtual mode, managed by a CEO and Directors with extensive international product development and partnering experience. Verva’s founding research was undertaken at the Metabolic Research Unit of Deakin University in Geelong, Australia; a state-of-the-art facility providing access to key in vitro and in vivo models and capabilities. Verva has subsequently engaged expert scientists, clinicians, technical advisers and contract research organisations worldwide to implement the Company’s research and development strategy.
Fibrotech Therapeutics
Series A in 2008
Fibrotech Therapeutics focuses on developing innovative drug candidates aimed at treating fibrosis related to various chronic conditions. The company's research and development efforts are directed towards addressing diseases such as diabetic nephropathy, kidney diseases, heart failure, pulmonary fibrosis, and arthritis. Founded in 2006 and based in Wonga Park, Australia, Fibrotech Therapeutics is dedicated to improving patient outcomes through its targeted therapeutic solutions.
Spinifex Pharmaceuticals
Series A in 2008
Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.
TenasiTech
Seed Round in 2008
TenasiTech is a provider of composite polymers tailored for various industries, including engineering, sporting, automotive, and construction. The company specializes in developing polymer products that exhibit mechanical strength, creep resistance, compressive set chemical resistance, and thermo-stability. These properties enhance the durability of engineering thermoplastics, making them more resistant to surface damage and suitable for demanding applications across multiple sectors.
BT Imaging
Series A in 2008
BT Imaging is a leading manufacturer of electrical-inspection equipment tailored for the photovoltaic manufacturing industry. The company specializes in luminescence-based inspection and quality control systems designed to enhance the production processes of silicon blocks, wafers, and solar cells. By providing advanced tools for research, product development, and manufacturing inspection, BT Imaging enables its clients to improve factory yield and increase the efficiency of solar cells. Their solutions support the overall design and production of solar modules, contributing to advancements in the solar energy sector.
Pepfactants
Series B in 2007
Pepfactants has developed a new way to break apart industrial emulsions, including those found in oil & gas operations, environmental remediation and other manufacturing processes. The company has discovered a chemical additive for demulsify the emulsions, where the additive is cheaper than many alternatives, and withstands extreme levels of salt and other contaminants. The chemical is readily available today as it is used for other, unrelated applications.
Fultec Semiconductor
Series C in 2006
Fultec Semiconductor is a circuit protection semiconductor company based in Mountain View, California, founded in 2001. It specializes in transient blocking devices designed to protect telecommunication and data communication systems from over-voltage and over-current incidents. The company's products provide wide bandwidth circuit protection against various electrical disturbances, including lightning, power induction, power cross, and short circuit events. Fultec's solutions serve multiple applications across sectors such as telecommunications, data communications, sensors, automotive, and power distribution. As of October 2008, Fultec Semiconductor operates as a subsidiary of Bourns, Inc.
OPAL Therapeutics
Series A in 2005
OPAL Therapeutics Pty Limited operates as an immunotherapy development company in Australia. It develops therapies for the treatment of human immunodeficiency virus, Hepatitis C, and chronic infection. OPAL Therapeutics Pty Limited was incorporated in 2005 and is based in Melbourne, Australia.
Spinifex Pharmaceuticals
Series A in 2005
Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.
Hatchtech
Venture Round in 2005
Hatchtech is an Australian company focused on developing innovative pest control solutions through its proprietary technology platform. The company's patented approach targets the egg hatch of pest species, effectively disrupting their lifecycle with a novel mode of action. Hatchtech's technology is designed to address various invertebrate pests, including ectoparasites such as head lice, as well as pests affecting animals, crops, and the built environment. Their flagship product offers a single-dose treatment that eliminates both head lice and their eggs in one application, providing an effective solution for infestations.
QRxPharma
Series A in 2002
QRxPharma Limited is an Australian pharmaceutical company focused on the research, development, and commercialization of biopharmaceutical products primarily in pain management and abuse prevention. The company is known for its Dual Opioid platform technology, which features a patented combination of morphine and oxycodone aimed at enhancing pain relief. Additionally, QRxPharma has developed Stealth Beadlets™, a proprietary technology designed to prevent drug abuse by incorporating deterrent features into solid dosage forms. The company has strategic agreements with various partners for the commercialization of its lead product candidate, immediate release MOXDUO®, which is intended for the treatment of acute pain. QRxPharma's clinical pipeline includes both intravenous and controlled release formulations of MOXDUO. Although QRxPharma does not currently have significant operations, it continues to pursue the development of its product portfolio aimed at improving patient outcomes and reducing risks associated with pain management therapies.
Wedgetail Communications
Seed Round in 2001
Wedgetail Communications develops security technology for all classes of network devices.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.